Literature DB >> 29181039

Epidemiology and Genetic Diversity of Colistin Nonsusceptible Nosocomial Acinetobacter baumannii Strains from Russia for 2013-2014.

Eugene A Sheck1, Mikhail V Edelstein1, Marina V Sukhorukova1, Natali V Ivanchik1, Elena Yu Skleenova1, Andrey V Dekhnich1, Ilya S Azizov1, Roman S Kozlov1.   

Abstract

A high level of resistance to carbapenems in Acinetobacter baumannii strains severely limits therapeutic possibilities. Colistin is the last resort drug against such strains, although the cases of resistance to this drug have become more frequent. This article presents the epidemiological features and genetic diversity of colistin nonsusceptible A. baumannii strains collected as part of a national multicenter epidemiological study of the antibiotic resistance of pathogens of nosocomial infections (MARATHON), which was conducted in 2013-2014 in Russia. A total of 527 A. baumannii isolates were collected, 10 (1.9%) of which were nonsusceptible to colistin. The majority of nonsusceptible A. baumannii isolates to colistin showed resistance to carbapenems and had the genes of the acquired OXA-40-like carbapenemases (n = 6). In one case, a combination of OXA-23-like + OXA-40-like (n = 1) genes was identified. One strain had the multidrug-resistant (MDR) phenotype, 6 isolates had extensively drug-resistant (XDR) phenotype, and 3 isolates had pandrug-resistant (PDR) phenotype. Among the colistin nonsusceptible A. baumannii isolates, 6 individual genotypes were identified, most of which belonged to successful international clones (CC92OXF/CC2PAS, n = 4; CC944OXF/ST78PAS, n = 4; CC109OXF/CC1PAS, n = 1).

Entities:  

Year:  2017        PMID: 29181039      PMCID: PMC5664240          DOI: 10.1155/2017/1839190

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


1. Introduction

Acinetobacter baumannii is one of the most troublesome pathogens of nosocomial infections [1, 2]. This pathogen is characterized by intrinsic resistance to a number of drugs, as well as an outstanding ability to acquire the determinants of antibiotic resistance through horizontal gene transfer, which led to a high level of A. baumannii strains resistance to almost all available antibiotics [3, 4]. A high level of in vitro sensitivity is retained only for colistin [5], which makes it possible to use it against the extensively drug-resistant A. baumannii strains [6]. At the same time, the cases of resistance to colistin become more frequent [7-9], which determines the necessity to monitor resistance to colistin among nosocomial A. baumannii strains. In addition, the spread of the multidrug-resistant (MDR) phenotype is mainly related to the spread of international high-risk clones and the horizontal transfer of antibiotic resistance genes [10, 11], which provoke the interest in studying the molecular epidemiology of colistin nonsusceptible strains. The purpose of the research is to study the epidemiology and genetic diversity of colistin nonsusceptible A. baumannii strains, isolated from clinical samples of hospitalized patients in different regions of Russia in 2013-14.

2. Materials and Methods

Clinical strains of microorganisms were collected as part of a multicenter epidemiological surveillance study of the antibiotic resistance of nosocomial pathogens (MARATHON) [12] in 21 cities of Russia from January 2013 to December 2014. 527 nosocomial isolates of A. baumannii were collected. In this study, only colistin nonsusceptible strains (MIC > 2 mg/L) were analyzed. Species identification was performed by the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS) using Microflex LT mass spectrometer and MALDI Biotyper Compass software v. 4.1.70 (Bruker Daltonics, Germany). The value of “Score” ≥ 2.0 was accepted as a measure for the reliable identification. Minimal inhibitory concentrations of antimicrobials have been determined by broth microdilution method with Mueller Hinton broth (Oxoid, United Kingdom) in accordance with ISO 20776-1:2006 [13]. Interpretation of MIC in clinical susceptibility categories of A. baumannii isolates to antimicrobial agents was performed according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) Breakpoint tables v.7.1 [14] (for aminoglycosides, carbapenems, ciprofloxacin, trimethoprim/sulfamethoxazole, and colistin) and also Clinical and Laboratory Standards Institute CLSI M100-S27 [15] (for penicillins with β-lactamase inhibitors and extended-spectrum cephalosporins). Isolates with tigecycline MIC of >1 mg/L were considered insusceptible to this drug [16]. Escherichia coli ATCC®25922, E. coli ATCC®35218, and Pseudomonas aeruginosa ATCC®27853 were used as control strains. DNA extraction was performed by express method by using InstaGene™ matrix (Bio-Rad, USA). Samples of extracted DNA were stored at −20°С before testing. Detection of genes encoding the most common carbapenemases of class D (OXA-23, OXA-24/40, and OXA-58) and metal β-lactamases (VIM, IMP, and NDM) was carried out by real-time PCR using commercial kits “AmpliSens® MDR Acinetobacter-OXA-FL” and “AmpliSens® MDR MBL-FL” (InterLabService, Russia) and DTPrime 5X1 system (DNA Technology, Russia). A. baumannii, A. pittii, and P. aeruginosa strains from proper collection, producing known carbapenemases of the listed groups, were used as positive controls. Genotyping was performed by single-nucleotide polymorphism (SNP) typing method [17]. Briefly, this method is based on analysis of 21 informative SNPs in 10 chromosomal loci (gltA, recA, cpn60, gyrB, gdhB, rpoD, fusA, pyrG, rplB, and rpoB) and is used at the University of Oxford and the Pasteur Institute multilocus sequence typing (MLST) schemes. A. baumannii strains of known sequence types from proper collection were used as positive controls. The comparison of received SNP profiles with MLST data was done using a web resource: http://snptab.antibiotic.ru [18]. Cluster analysis of SNP profiles was performed using PHYLOViZ 2.0 software (http://www.phyloviz.net/).

3. Results and Discussion

Ten of 527 (1.9%) nosocomial colistin nonsusceptible A. baumannii isolates were isolated from 7 hospitals in 7 cities of Russia in 2013-2014. The results of antimicrobial susceptibility testing for these isolates are presented in Table 1. The MIC of colistin 4 mg/L was detected in 1 isolate, while the remaining isolates (n = 9) had high levels of resistance (MIC range: 32–256 mg/L).
Table 1

Characteristic of nosocomial colistin nonsusceptible A. baumannii strains.

IsolateSourceCityYearClonal groupCarbapenemase MIC (mg/L)/clinical categoryCategory
Ampicillin/sulbactamPiperacillin/tazobactamCefotaximeCeftazidimeCefepimeImipenemDoripenemMeropenemGentamicinTobramycinAmikacinCiprofloxacinTigecyclineColistinTrimethoprim/sulfamethoxazole
MAR13-1673UTSmolensk2013CC944OXF/ST78PASOXA-40-like16816483246425664128128225616XDR
ISISSRRRRRRRRRR
MAR13-1674RTSmolensk2013CC944OXF/ST78PASOXA-40-like128128256322563264128256256512128825632PDR
RRRRRRRRRRRRRRR
MAR13-1680SSTSmolensk2013CC109OXF/СС1PASOXA-40-like162562562562560.548256256512128225632XDR
IRRRRSRIRRRRRRR
MAR13-1127RTMurmansk2013CC92OXF/СС2PASOXA-40-like64256256643264128128323216128832256PDR
RRRRRRRRRRIRRRR
MAR13-1452SSTOmsk2013CC92OXF/СС2PASOXA-23-like,OXA-40-like25625625625625632128642562565121284256256PDR
RRRRRRRRRRRRRRR
MAR14-236UTSmolensk2014CC92OXF/СС2PASNegative64256256256256248256256512321128128XDR
RRRRRSRIRRRRSRR
MAR14-1518BTomsk2014CC92OXF/СС2PASNegative6425625625625621125612566441282XDR
RRRRRSSSRSRRRRS
MAR14-1542SSTTolyatti2014CC490OXF/CC25PASNegative81282562563211125616646411284MDR
SRRRRSSSRRRRSRI
MAR14-2675IAIzhevsk2014CC944OXF/ST78PASOXA-40-like256256256256256128641282562565121280.5128128XDR
RRRRRRRRRRRRSRR
MAR14-3743RTPenza2014CC944OXF/ST78PASOXA-40-like322562561281283232642562565121280.541XDR
RRRRRRRRRRRRSRS

UT: urinary tract; RT: respiratory tract; SST: skin and soft tissue; B: blood; IA: intra-abdominal.

The majority of colistin nonsusceptible A. baumannii isolates were also resistant to carbapenems and were the carriers of genes of acquired OXA type carbapenemases, mainly OXA-40-like (n = 6). One isolate was shown to possess simultaneously genes encoding two different carbapenem hydrolyzing oxacillinases: OXA-23-like and OXA-40-like. Expectedly high resistance was detected to all other β-lactams. At the same time, associated resistance to drugs of other groups with high MIC values is observed (range of gentamicin MIC: 32–256 mg/L; amikacin: 16–256 mg/L; ciprofloxacin: 32–128 mg/L). Only one tobramycin susceptible isolate was found (MIC = 1 mg/L), while the MIC for the remaining isolates was in the range 16–256 mg/L. Two isolates were susceptible to combination of trimethoprim-sulfamethoxazole (MIC range: 1-2 mg/L), while for the remaining isolates the MIC was in the range 4–128 mg/L. Six isolates had tigecycline MICs of 2 to 8 mg/L and thus were considered as resistant. In accordance with international criteria [19], 1 isolate was defined as multidrug-resistant (MDR), 6 isolates were defined as extensively drug-resistant (XDR), and 3 isolates were defined as pandrug-resistant (PDR). Most infections associated with colistin nonsusceptible A. baumannii isolates were detected as single cases in different cities of Russia. An exception is Smolensk, from which 4 isolates were isolated in one hospital. In this connection, it seemed interesting to evaluate the population structure of studied strains. Colistin nonsusceptible A. baumannii isolates belonged to 6 genotypes (Figure 1). Three genotypes differed from each other in no more than 2 positions and were united in a single genetic cluster as related genotypes. This cluster included 4 isolates from 4 cities and corresponded to the international clone CC92OXF/CC2PAS (according to the MLST schemes of the University of Oxford and the Pasteur Institute, resp.). Another genotype included 4 isolates from 3 cities and corresponded to CC944OXF/ST78PAS. The strains of this genetic lineage are widespread in the territory of Russia and Belarus [12] and, according to the literature, were found in Italy, the US, and Germany [20-23]. This allows considering this genotype as a new international clone. Two isolates belonged to individual genotypes: one of them corresponded to the international clone CC109OXF/CC1PAS and the other to the clonal complex CC490OXF/CC25PAS. All isolates with XDR and PDR phenotypes belonged to the international epidemic clones CC92OXF/CC2PAS, CC944OXF/ST78PAS, and CC109OXF/CC1PAS.
Figure 1

UPGMA clustering of SNP profiles of colistin nonsusceptible A. baumannii strains. The length of each rectangle depends on the number of isolates. International epidemic clones are marked with dashed lines. Color detailed the resistance categories (MDR, XDR, and PDR) of isolates within each genotype.

4. Conclusion

Thus, colistin nonsusceptible A. baumannii strains described in this study relate to different genetic lineages and mainly belong to distinct international high-risk clones. The accumulation of molecular typing data is an important element in understanding the roots and epidemiology of colistin resistance and in predicting its further spread.
  16 in total

1.  Carbapenem-resistant Acinetobacter baumannii ST78 with OXA-72 carbapenemase and ESBL gene blaCTX-M-115.

Authors:  Yvonne Pfeifer; Klaus-Peter Hunfeld; Stefan Borgmann; Daniela Maneg; Wolfgang Blobner; Guido Werner; Paul G Higgins
Journal:  J Antimicrob Chemother       Date:  2016-01-17       Impact factor: 5.790

Review 2.  Resistance to polymyxins in Gram-negative organisms.

Authors:  Katy Jeannot; Arnaud Bolard; Patrick Plésiat
Journal:  Int J Antimicrob Agents       Date:  2017-02-03       Impact factor: 5.283

Review 3.  Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.

Authors:  Marie Kempf; Jean-Marc Rolain
Journal:  Int J Antimicrob Agents       Date:  2011-11-22       Impact factor: 5.283

4.  Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a tertiary care hospital in Naples, Italy, shows the emergence of a novel epidemic clone.

Authors:  Maria Giannouli; Susanna Cuccurullo; Valeria Crivaro; Anna Di Popolo; Mariano Bernardo; Federica Tomasone; Gerardino Amato; Sylvain Brisse; Maria Triassi; Riccardo Utili; Raffaele Zarrilli
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

Review 5.  Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii.

Authors:  Nabil Karah; Arnfinn Sundsfjord; Kevin Towner; Ørjan Samuelsen
Journal:  Drug Resist Updat       Date:  2012-07-27       Impact factor: 18.500

6.  Eighteen years of experience with Acinetobacter baumannii in a tertiary care hospital.

Authors:  L Silvia Munoz-Price; Kristopher Arheart; Patrice Nordmann; Anne E Boulanger; Timothy Cleary; Rebeca Alvarez; Louis Pizano; Nicholas Namias; Daniel H Kett; Laurent Poirel
Journal:  Crit Care Med       Date:  2013-12       Impact factor: 7.598

Review 7.  In Vitro Activity of Tigecycline Against Acinetobacter baumannii: Global Epidemiology and Resistance Mechanisms.

Authors:  Spyros Pournaras; Vasiliki Koumaki; Vasiliki Gennimata; Evangelia Kouskouni; Athanassios Tsakris
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 8.  Screening and deciphering antibiotic resistance in Acinetobacter baumannii: a state of the art.

Authors:  Rémy A Bonnin; Patrice Nordmann; Laurent Poirel
Journal:  Expert Rev Anti Infect Ther       Date:  2013-06       Impact factor: 5.091

Review 9.  Acinetobacter baumannii: evolution of a global pathogen.

Authors:  Luísa C S Antunes; Paolo Visca; Kevin J Towner
Journal:  Pathog Dis       Date:  2014-01-27       Impact factor: 3.166

10.  Virulence-related traits of epidemic Acinetobacter baumannii strains belonging to the international clonal lineages I-III and to the emerging genotypes ST25 and ST78.

Authors:  Maria Giannouli; Luísa C S Antunes; Veronica Marchetti; Maria Triassi; Paolo Visca; Raffaele Zarrilli
Journal:  BMC Infect Dis       Date:  2013-06-20       Impact factor: 3.090

View more
  2 in total

1.  Emergent Polymyxin Resistance: End of an Era?

Authors:  Zekun Li; Yuping Cao; Lingxian Yi; Jian-Hua Liu; Qiwen Yang
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

2.  Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings.

Authors:  Mariana Neri Lucas Kurihara; Romário Oliveira de Sales; Késia Esther da Silva; Wirlaine Glauce Maciel; Simone Simionatto
Journal:  Rev Soc Bras Med Trop       Date:  2020-11-06       Impact factor: 1.581

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.